Filter by business model, region, score band and the documents each supplier publishes.
Loading directory…
Vadodara drug maker, dating to 1907, with three API plants and six formulation plants. Holds US DMFs for 6 peptide APIs, including glatiramer and tirzepatide.
RK Pharma subsidiary offering API process R&D, custom synthesis and generic APIs, with US offices and plants in Gujarat and Andhra Pradesh. Holds US DMFs for 6 peptide APIs.
Aspen Pharmacare's API site in Oss, Netherlands, with roots in 1923; makes peptides with a liquid-phase process plus hormones and heparin. Holds US DMFs for 4 peptide APIs.
Tianjin unit of Asymchem, a CDMO listed in Shenzhen and Hong Kong that makes peptides and oligos; US DMFs for liraglutide and semaglutide.
Peptide API subsidiary of Aurobindo Pharma with a plant near Hyderabad. Makes generic peptide APIs and runs GMP contract projects from mg to kg scale.
Privately owned Barcelona peptide CDMO founded in 1989, making GMP generic peptide APIs and custom NCE peptides. Holds US DMFs for 10 peptide APIs.
Bengaluru biopharma company that makes generic APIs and complex formulations, including GLP-1 peptides. Holds US DMFs for liraglutide, semaglutide and tirzepatide.
Changzhou API and tablet maker founded 1949 with a record of US FDA, EU GMP and PMDA inspections; US DMFs for semaglutide and tirzepatide.
Hangzhou peptide CRDMO founded in 2001, part of CPC Scientific/Medtide, with production in China and the USA. Holds US DMFs for cetrorelix, semaglutide and tirzepatide.
Taiwanese API maker founded in 1964, trading as Cenra API Solutions, offering CMO/CDMO services. Holds US DMFs for difelikefalin, plecanatide and setmelanotide.
Mumbai drugmaker founded in 1936 with six plants, including a US-FDA-accredited API site at Roha; holds an active US DMF for semaglutide.
Hyderabad injectables CDMO founded 1978, promoted by Fosun Pharma; FDA-inspected sites; US DMF for glatiramer acetate.
Gwangju peptide API maker founded in 2000 as Anygen, KOSDAQ-listed since 2016, with MFDS-approved GMP peptide plants; holds US DMFs for ganirelix and vasopressin.
Riga drug maker operating since 1946 that now offers CDMO services; WHO-inspected oxytocin API site; US DMF for oxytocin.
Hyderabad-based MSN Group entity holding US DMFs for 11 peptide APIs, including semaglutide and tirzepatide. MSN runs 27 plants in India, the USA and Indonesia.
Indian CDMO whose Turbhe, Navi Mumbai site develops and makes peptide APIs by solid- and solution-phase synthesis. Holds US DMFs for 9 peptide APIs.
Hamburg microbial biologics CDMO founded 1987, now wholly owned by Gedeon Richter; FDA-inspected 2013, 2018 and 2026; US DMF for teriparatide.
Raichur API and CDMO subsidiary of Shilpa Medicare; US DMFs for desmopressin, liraglutide and octreotide; Raichur units inspected by US FDA in 2025.
Neijiang, Sichuan injectables and API maker founded in 2010, listed on Shanghai's STAR Market, with FDA and UK MHRA GMP inspections; holds an active US DMF for lanreotide.
Jiangsu peptide CDMO and generic API supplier with large automated SPPS capacity; states it has passed four US FDA inspections. Holds US DMFs for 9 peptide APIs.
Dutch holding entity of TAPI, Teva's API and CDMO business, with peptide development and GMP production across a global plant network. Holds US DMFs for 9 peptide APIs.
Chinese maker of generic small-molecule, peptide and oligonucleotide APIs, founded in 1998, with an FDA-inspected site in Yangzhou. Holds US DMFs for semaglutide and tirzepatide.
Privately held CDMO with peptide synthesis from discovery to commercial scale.
US peptide API CDMO with facilities in the US and China.
Swiss peptide and oligonucleotide CDMO with GMP plants in Europe and the US.
Greek peptide manufacturer producing GMP and non-GMP peptides and resins.
French API producer spun out of Sanofi. Its Frankfurt site at Hoechst Industrial Park runs a CDMO platform for peptide and oligonucleotide development and cGMP manufacture.
Chinese peptide drug manufacturer producing APIs and finished products.
Belgian biotech firm and CDMO, part of Kaneka, selling research peptides, oligos and antibodies and running GMP manufacturing that it says is FDA inspected.
Peptide, HPAPI and bioconjugate manufacturing within Lonza's small-molecule business.
Indian API manufacturer and CDMO with a peptide synthesis platform.
Peptide-focused CDMO running GMP manufacturing sites on three continents.
API manufacturer and CDMO focused on complex generics, including peptides.
Privately owned Swiss CDMO near Zurich, in business since 1963, that makes peptide APIs, peptide fragments and amino acid derivatives by solid- and solution-phase synthesis.
Peptide and oligonucleotide CRDMO unit of WuXi AppTec, covering discovery through API and drug product manufacture. WuXi STA's peptide projects are routed to this platform.
Ajinomoto group CDMO for small molecules, oligonucleotides, peptides and biologics. It makes GMP peptides with its AJIPHASE liquid-phase process at sites in Belgium and Japan.
Beijing API company, founded 2006, that holds DMFs and has its APIs made in partner facilities under its own quality control. Holds US DMFs for 13 peptide APIs.
US generics, specialty and biosimilars company with operations in the US, India and Ireland; US DMF for glatiramer acetate.
Nanjing API subsidiary of Nasdaq-listed Amphastar; US DMF for teriparatide.
Fremont, California peptide maker founded in 1993, now a subsidiary of Kaneka Eurogentec, offering catalogue, custom and GMP-grade peptides and assay kits.
Texas custom synthesis company in business since 1984, making peptides, oligonucleotides and bioconjugates at its Lewisville facility.
Hyderabad API developer and maker founded in 2007, focused on niche and complex products. Holds US DMFs for cetrorelix, icatibant and sincalide.
California peptide synthesizer maker founded 1993 that also runs a cGMP peptide CDMO site in Milpitas; US DMF for triptorelin.
Italian API maker in the Italfarmaco Group, founded 1973, producing peptides since 1996; US DMFs for leuprolide and octreotide.
Chongqing maker of diabetes and obesity drugs, active since 2015 and controlled by Zhifei (300122) since 2025; US DMFs for liraglutide and semaglutide.
Chongqing API maker founded in 2016 covering high-potency APIs, peptides and XDC compounds with CDMO services; reports FDA on-site inspections in 2024 and 2025 and holds a US DMF for semaglutide.
European CDMO network with a dedicated peptide, lipid and carbohydrate platform.
Fresenius Kabi's Italian API unit; its Villadose site near Venice develops and makes peptide APIs, also offered through Fresenius Kabi contract manufacturing. Holds US DMFs for 6 peptide APIs.
Life-science services company with a large custom peptide synthesis service.
Hangzhou recombinant drug maker listed in Hong Kong (02566), formerly Huadong Medicine's gene engineering centre; US DMF for liraglutide.
Hangzhou drug maker incorporated 1993, part of Shenzhen-listed Huadong Medicine; two group entities hold US DMFs for semaglutide.
Mumbai peptide API maker acquired by Piramal Pharma in 2021; its oxytocin API is WHO-prequalified; US DMF for oxytocin.
Main operating subsidiary of Hong Kong-listed Hansoh Pharma, founded 1995; holds US DMFs for degarelix and icatibant.
Shanghai recombinant protein and enzyme maker, listed on the STAR Market, offering CMC development and GMP manufacturing; holds a US DMF for a semaglutide peptide fragment.
Osaka-based maker of research peptides, glyco compounds and amino acid reagents since 1977, also offering custom synthesis and GMP peptide drug development.
German peptide maker founded in 2001 near Berlin, selling catalogue peptides and peptide pools and offering custom synthesis on in-house built synthesis robots.
Korean peptide drug developer founded in 1997 that also runs an ISO 9001-certified custom peptide synthesis service and markets a 3.75 mg depot injection.
Austrian CDMO for GMP peptide APIs at milligram to hectogram scale.
Chinese end-to-end CDMO with a peptide and oligonucleotide (TIDES) platform. It runs manufacturing sites in China and in New Jersey, USA.
Heidelberg company founded in 2000 that synthesizes custom peptides and produces specific antibodies from the Heidelberg Technology Park.
Indian contract research, development and manufacturing organization (CRDMO) listed on NSE and BSE. It has opened a dedicated Peptide Research Center in Hyderabad.
Shenzhen peptide CDMO and API maker founded in 2009, with 13 cGMP lines and 85,000 L of SPPS/LPPS reactor volume. Holds US DMFs for 6 peptide APIs.
Shenzhen-listed drug maker (002294) selling APIs and finished products; US DMF for bivalirudin.
API CDMO with sites in the UK, Ireland and the US. Its Cork, Ireland facility focuses on peptide manufacturing and large-scale chromatography.
Suzhou API and intermediate maker founded in 2000 offering CDMO/CMO services; holds an active US DMF for semaglutide.
Suzhou peptide API and formulation maker founded in 2000, flagship of Tianma Pharma Group, offering CRO/CMO/CDMO services. Holds US DMFs for 8 peptide APIs.
Thermo Scientific custom peptide service making research peptides of 2-110 amino acids by Fmoc solid-phase synthesis, plus peptide libraries and AQUA heavy peptides.
Dubai-incorporated subsidiary of Zydus Lifesciences, the Ahmedabad drug group listed in India; US DMF for semaglutide.
Research compound store run by Vertex Labs LLC, with lot-by-lot COAs hosted by Freedom Diagnostics and lookup by vial lot or lab accession number.
New York-based research peptide seller with a COA library indexed by its own batch codes, citing Verum Analytics as the testing lab.
Houston-based seller of research peptides and blends with lot-numbered COAs from Janoshik Analytical and endotoxin data listed per product.
Online seller of research-use peptides and blends with batch COAs from Janoshik Analytical and US labs, plus a rotating heavy metal, endotoxin and sterility panel.
Guangzhou factory-direct research peptide and private-label OEM supplier with a public lot COA library; sample orders from one 10-vial kit.
Family-run Texas LLC selling research peptides since 2024, with batch records from Freedom Diagnostics, Kovera, MDx and Precision Mass Spec.
Markham, Ontario research peptide seller run by ACCUTIDE Research Supply Inc., publishing batch COAs with HPLC purity and Kinetic LAL endotoxin results; wholesale minimum 30 units.
UK lab in Redditch that synthesizes custom research peptides and peptide libraries and also runs UKAS-accredited amino acid analysis and protein sequencing.
Sydney research peptide seller (ABN 79 700 194 074) that publishes 18 Janoshik COAs with lot and test dates; bulk orders by enquiry.
Beijing biotech founded in 2018 that develops and produces recombinant protein and peptide drugs in E. coli for metabolic disease; holds an active US DMF for semaglutide.
Canadian life science research supplier, headquartered in Markham, Ontario and Amherst, New York, offering custom and GMP peptide and oligo synthesis.
Orlando-based seller of 100+ research peptides and blends, with batch COAs from Vanguard Laboratory (HPLC purity only).
Swiss Debiopharm plant in Martigny making triptorelin sustained-release products; US DMF for triptorelin pamoate microgranules.
Shanghai bulk peptide maker supplying wholesalers; holds US DMFs for bremelanotide, semaglutide and tirzepatide.
Putian, Fujian peptide API maker founded in 2019 by New Hope and Taiwan's Genovior, focused on GLP-1 APIs. Holds US DMFs for semaglutide and tirzepatide.
Shanghai maker of protected amino acids, custom and catalogue peptides, drug peptides, cosmetic peptides and antibodies, with eight production bases.
Zunyi, Guizhou peptide manufacturer offering development and kg-scale production; holds active US DMFs for tirzepatide and other peptides.
Hangzhou peptide and oligonucleotide CRDMO supporting projects from preclinical to commercial supply; holds active US DMFs for tirzepatide and inclisiran.
Hangzhou peptide maker founded in 2014 offering pharmaceutical, cosmetic and catalog peptides plus peptide CRO/CDMO work; holds an active US DMF for semaglutide.
Hangzhou peptide developer offering peptide APIs, intermediates, impurities and ADC/PDC linkers plus custom synthesis and process development; holds an active US DMF for tirzepatide.
Hangzhou peptide API maker and CDMO founded in 2019, supplying therapeutic and cosmetic peptides. Holds US DMFs for linaclotide, semaglutide and tirzepatide.
Privately held Hyderabad generics and API group with 36+ plants; US DMFs for semaglutide and vasopressin.
Hong Kong wholesale research peptide supplier holding factory lots in a Kwun Tong warehouse, offering private label and COAs on request.
Tübingen peptide company with about 30 years in peptide synthesis, making custom peptides, libraries, arrays, PNAs and neoantigen vaccine peptides.
Changchun biopharmaceutical maker of somatropin, semaglutide and other APIs; holds active US DMFs for semaglutide and somatropin.
Berlin peptide maker offering custom synthesis, peptide catalogues, peptide pools, microarrays and pre-GMP peptides, with a TÜV Rheinland-certified ISO 9001 system.
Wyoming LLC selling research peptides to registered customers, claiming a per-batch ISO 17025 lab panel with endotoxin, sterility and residual TFA.
New Jersey contract research company founded in 2008 that makes custom peptides, peptide conjugates and PNAs, and also provides protein and antibody services.
Nanjing supplier of insulin and metabolic peptide APIs with technology transfer services; US DMFs for semaglutide and tirzepatide.
Ningxia API and peptide maker founded in 2016 in Pingluo, offering peptide API development and manufacturing; holds US DMFs for semaglutide and tirzepatide.
Australian-facing research peptide shop owned by Hong Kong company Global Bio Research Limited, selling from local Australian stock in AUD.
UK custom peptide maker trading as Peptide Synthetics. It says it synthesizes every peptide in its own Hampshire laboratory and outsources none.
Japanese CDMO set up in 2017 to develop and manufacture special peptide and oligonucleotide APIs, from milligram samples to multi-kilogram GMP batches.
UK research peptide reseller operated by JUICE IT UP LTD, offering batch lookup of supplier and third-party documents.
Weihai Sino-US joint venture founded 2016 making peptide APIs and cosmetic peptides; US DMFs for leuprolide and semaglutide.
Navi Mumbai biopharma and specialty pharma company; US DMFs for lanreotide and liraglutide.
Guangzhou research peptide maker and private-label OEM with a public lot COA library; samples from one 10-vial kit, private label from 100 kits.
Shenzhen peptide company founded in 2020 making GLP-1 peptide APIs, sterile vials and peptide reference materials at a Zhongshan plant; holds an active US DMF for tirzepatide.
Shenzhen synthetic-biology ingredient maker with semaglutide as its lead biopharma product; US DMFs for semaglutide main chain and side chain.
Leshan-based peptide producer founded in 2015 with SPPS and LPPS lines; holds US DMFs for eptifibatide, semaglutide and tirzepatide.
Suzhou peptide CRDMO with GMP workshops built to ICH Q7; US DMFs for semaglutide and tirzepatide.
Suzhou API and intermediates producer offering customized manufacturing. Holds US DMFs for semaglutide, thymalfasin and tirzepatide.
Belfast-registered research peptide seller publishing HPLC purity, LAL endotoxin certificates and SDS files for each product.
Wuhan fermentation-based CDMO founded 2008 making GLP-1 APIs, proteases and cell products; US DMFs for semaglutide and its main chain.
Research peptide store operated by Xcel Research LLC that sells only to registered researchers, with third-party testing claimed but no lab named.
Nantong company founded in 2020 that makes peptides by biosynthesis and offers peptide CMC development. Holds US DMFs for semaglutide and tirzepatide.
Hangzhou company founded in 2020 that makes GLP-1 peptides by fermentation plus semi-synthesis; holds an active US DMF for semaglutide API.
Austin, Texas seller of research peptides, aminos, bioregulators and neuroactives, claiming US lyophilization and testing by three outside labs.
Kansas City research peptide store with a library of about 122 downloadable COAs; the testing lab is not named in page text.
Ohio research peptide seller with COAs from SafeCert, BioRegen (COA number plus security key) and AV Analytics; also sells capsules and creams.
Las Vegas-listed seller of lyophilized research peptides such as AOD-9604 and BPC-157, claiming third-party HPLC-MS batch testing.
Sofia-based EU research peptide shop (UIC 208627334) linking Janoshik verification pages for purity, endotoxin, sterility and heavy-metal tests; also sells capsules and nasal sprays.
Austin, Texas seller of research peptides such as retatrutide, Semax, Selank and GLOW, with batch COAs from Janoshik and ACS Laboratories.
Wyoming LLC selling 100+ research peptides and blends with Janoshik COAs carrying task numbers and keys, plus sterility, endotoxin and heavy-metal testing.
Pensacola, Florida seller of research peptides, blends, capsules, sprays and bioregulators, with professional pricing behind login.
Canadian online research peptide shop registered in Alberta that says its batches are tested by Janoshik Analytical.
London research peptide seller (Companies House 17189709) with lab-hosted Janoshik reports covering purity, endotoxin and heavy metals; also sells pre-filled pens.
Idaho-based research peptide seller with batch-numbered, QR-linked COAs from US labs (Vanguard, Chromate, Freedom Diagnostics) and some capsule products.
Auckland research peptide seller that says each batch is tested by an independent New Zealand laboratory for identity and purity.
Wyoming-registered online seller of research peptides, with COAs from Janoshik and Freedom Diagnostics and products grouped by research goals such as fat loss.
Scottsdale research peptide seller with lot-numbered COAs from Vanguard, Eagle Analytical and others, covering sterility and endotoxin; also sells capsules.
Tallinn-based EU seller of research peptides and pre-blended kits, operated by Golden-Mobile OU, that cites Janoshik batch testing.
EU-shipping research peptide store run by Hong Kong company LONFAISE LIMITED that says its products are Janoshik-tested.
Liverpool research peptide shop that provides batch COAs on request and states third-party testing for purity, endotoxin, microbial counts and heavy metals.
Australian research peptide shop run by a sole trader (ABN 94 275 430 228, NSW) with a published COA library and PayID/bank payment.
London research peptide retailer (Companies House 17350045) with a COA library of Janoshik reports listed by product and batch.
Georgia seller of research peptides, blends, BPC-157 capsules and aerosol misters, claiming per-lot purity, heavy metal, endotoxin and sterility testing.
Leiden-based EU research peptide shop (KvK 42046001) whose certificate page links Janoshik test pages.
UK research peptide shop, a trading name of South Studios Ltd, that says every batch is tested by Janoshik and posts COA PDFs.
St. Petersburg, Florida seller of research peptides plus capsules, tablets and liquid sprays, with Kovera and Freedom Diagnostics reports.
Vancouver-based online shop for research peptides with a page of downloadable third-party COA PDFs and Canada Post Xpresspost delivery.
Shenzhen research peptide supplier and OEM storefront of China Biotech Group, established 2010, with a one-kit minimum order.
Florida research peptide seller operated by Melex Technologies Inc., with a lot/accession COA archive and sterility and endotoxin data on COAs from May 2026.
Connecticut research chemical seller of SARMs and peptides, citing MZ Biolabs and Colmaric Analyticals for HPLC and mass-spec testing.
London-addressed UK research peptide shop selling vials and peptide pens, with a COA-reading guide but no named testing lab.
Vancouver online seller of research peptides whose COA page lists batch codes and Freedom Diagnostics (USA) identity and purity results.
Melbourne (Carlton) research peptide seller with a COA image library for each product; testing lab not named.
Mumbai drug maker incorporated in 1935 with plants in India and the USA. Holds US DMFs for difelikefalin, icatibant and terlipressin. Pithampur FDA warning letter still open.
Online research peptide store with categories such as fat loss and muscle performance; FDA warning letter (March 2026) gives a Rancho Santa Fe, CA address.
Harbin peptide API maker founded in 2011. Holds US DMFs for 11 peptide APIs. FDA issued it a CGMP warning letter in May 2026 that remains open.
Florida research peptide store run by Lovega LLC with 50+ products and third-party testing claims; open FDA warning letter from March 2026.
Colorado research peptide seller with lot-coded COAs (Chromate verify links, Kovera, Vanguard), a 15-test panel and spray/capsule products. Open FDA letter.
Nanjing maker of peptide, protein and polysaccharide APIs and finished products, registered in 2017. Holds US DMFs for semaglutide and tirzepatide. FDA warning letter issued Nov 2026.
Research peptide store (pppepz.com) behind an age gate; FDA warning letter (August 2026) names founder and a Phoenix, Arizona address.
Sarasota research peptide store run by Pirsek Technologies LLC, publishing purity, endotoxin, heavy-metal and sterility files; open FDA warning letter.
Login-only research peptide store claiming third-party testing; FDA warning letter (March 2026) lists a Scottsdale, Arizona address.
Florida research peptide seller with COAs linked to Janoshik verification pages and its own batch codes; also sells capsules and tablets. Open FDA letter.
Mumbai-based generics group that makes APIs and finished medicines. Holds US Type II DMFs for 15 peptide APIs, including GLP-1s and GnRH analogues.
Texas research peptide store run by TXP Innovations LLC that claims third-party testing; it received an FDA warning letter in August 2026.
Mumbai drug maker with its own API and formulation plants in India. Holds US DMFs for 3 peptide APIs. Received an FDA CGMP warning letter in November 2026.
Login-only wholesale research peptide supplier powered by Sterling Path LLC in Brooksville, Florida; claims per-batch purity, identity and endotoxin tests.
Large Zhejiang API and generic drug maker founded in 1989 and listed in Shanghai; holds active US DMFs for semaglutide and a semaglutide intermediate. It has an open FDA warning letter from June 2025.